Twist Bioscience insider disposes 5,517 shares under 10b5-1 and sell-to-cover

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis reported two planned equity sales under Rule 10b5-1 and company tax-withholding procedures. On 10/08/2025 he sold 3,000 shares at $31.15 under a pre-established trading plan adopted on 05/08/2025. On 10/09/2025 he sold 2,517 shares at $32.922 to satisfy tax withholding for vested restricted stock units; the filing notes these "sell to cover" sales are mandatory under the equity incentive plan and not discretionary. Following these transactions he beneficially owned 91,525 shares.

Positive

• Use of a documented Rule 10b5-1 plan for the 3,000-share sale adds procedural compliance and reduces timing-risk concerns
• Sell-to-cover transaction for 2,517 shares is described as mandatory to satisfy tax withholding, indicating ordinary compensation mechanics rather than discretionary liquidation

Negative

• Total insider holdings decreased to 91,525 shares after the reported disposals, modestly reducing insider exposure
• Two consecutive sale dates within two days could draw investor attention even if both are routine

Insights

Corporate Governance Analyst

Insider sales were routine: one Rule 10b5-1 trade and mandated sell-to-cover for RSU taxes.

The first sale of 3,000 shares on 10/08/2025 was executed under a Rule 10b5-1 trading plan adopted on 05/08/2025, which provides an affirmative defense to insider trading claims when properly structured.

The second sale of 2,517 shares on 10/09/2025 is explicitly for tax withholding tied to RSU vesting and described as non-discretionary. Monitor upcoming SEC filings for additional plan activity or changes to beneficial ownership within the next reporting cycle.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		S		3,000(1)	D	$31.15	94,042	D
Common Stock	10/09/2025		S		2,517(2)	D	$32.922	91,525	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 8, 2025.

2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	10/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TWST CFO Adam Laponis sell and why?

He sold 3,000 shares on 10/08/2025 under a Rule 10b5-1 plan at $31.15 and 2,517 shares on 10/09/2025 at $32.922 to cover tax withholding on vested RSUs.

Was the 10/08/2025 sale discretionary or pre-planned?

The 3,000-share sale was executed under a previously adopted Rule 10b5-1 plan (adopted 05/08/2025), indicating it was pre-planned.

Does the filing state how many shares the reporting person owns after the trades?

Yes. The reporting person beneficially owned 91,525 shares following the reported transactions.

Are the sell-to-cover shares considered discretionary trades?

No. The filing states the 2,517-share sell-to-cover was mandated by the issuer's equity plan to satisfy tax withholding and is not a discretionary trade.

What prices were received for the reported sales?

The reported sale prices were $31.15 for the 3,000 shares and $32.922 for the 2,517 shares.